ALPMF - Astellas xospata misses primary endpoint in late-stage leukemia study

Astellas' (ALPMF) Xospata (gilteritinib) in combination with azacitidine did not meet the primary endpoint of overall survival at an interim analysis of Phase 3 trial, LACEWING in acute myeloid leukemia ((AML)) patients.Independent data monitoring committee recommended terminating the study for futility; Astellas has stopped enrollment.Trial involved 250 newly diagnosed FLT3 mutation-positive AML patients who were ineligible for intensive induction chemotherapy.

For further details see:

Astellas xospata misses primary endpoint in late-stage leukemia study